Posted by Michael Wonder on 14 Feb 2023
Mirum Pharmaceuticals submits supplemental new drug application to FDA for Livmarli in patients with cholestatic pruritus in progressive familial intrahepatic cholestasis
14 February 2023 - Submission based on MARCH Phase 3 study with high statistical significance (p<0.0001) between LIVMARLI versus placebo, and 62% of itch severity scores reported as mild to none.
Mirum Pharmaceuticals today announced that it has submitted a supplemental new drug application for Limmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis.
